Related Experiment Videos
Immunopathology of penicillamine-induced glomerular disease
Abstract:
Four patients with rheumatoid arthritis developed heavy proteinuria after 5 to 12 months of treatment with D-penicillamine. Light microscopy of renal biopsy samples showed minimal glomerular capillary wall thickening and mesangial matrix increase, or no departure from normal. Electron microscopy, however, revealed subepithelial electron-dense deposits, fusion of epithelial cell foot processes, and evidence of mesangial cell hyperactivity. Immunofluorescence microscopy demonstrated granular capillary wall deposits of IgG and C3. The findings were similar to those in early membranous glomerulonephritis, differences being observed however in the results of staining for the early-acting complement components Clq and C4. It is tentatively concluded that complement was activated by the classical pathway.
Insights
D-penicillamine treatment in rheumatoid arthritis patients can cause kidney damage, specifically heavy proteinuria. Renal biopsies revealed changes consistent with early membranous glomerulonephritis, suggesting complement activation.
Area of Science:
- Nephrology
- Rheumatology
- Immunopathology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease.
- D-penicillamine is a medication used to treat RA.
- Drug-induced nephropathies are a known complication of some medications.
Purpose of the Study:
- To investigate the renal pathology in rheumatoid arthritis patients treated with D-penicillamine who developed heavy proteinuria.
- To characterize the glomerular changes using various microscopy techniques.
- To determine the mechanism of kidney injury, particularly the role of complement.
Main Methods:
- Analysis of renal biopsy samples from four RA patients with proteinuria.
- Light microscopy (LM) to assess glomerular structure.
- Electron microscopy (EM) for ultrastructural examination of podocytes and basement membranes.
- Immunofluorescence microscopy (IFM) to detect immune deposits and complement components.
Main Results:
- Patients developed heavy proteinuria after 5-12 months of D-penicillamine therapy.
- LM showed minimal glomerular changes; EM revealed subepithelial electron-dense deposits and podocyte foot process effacement.
- IFM demonstrated granular IgG and C3 deposition along capillary walls, indicative of immune complex glomerulonephritis.
- Distinct staining patterns for C1q and C4 suggested classical complement pathway activation.
Conclusions:
- D-penicillamine-induced nephropathy in RA patients resembles early membranous glomerulonephritis.
- The findings suggest immune complex deposition and activation of the classical complement pathway contribute to renal injury.
- Close monitoring for proteinuria is crucial in RA patients receiving D-penicillamine.